# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

F. Proprietary and Established Names:

QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard Fastec $^ \mathrm { { \textregistered } }$ II PPX Drug Screen Dipstick Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipstick

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JXN</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>862.3700  Propoxyphene test system</td><td rowspan=1 colspan=1>91-Toxicology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below

2. Indication(s) for use:

The Fastect $^ \mathrm { \textregistered }$ II PPX Drug Screen Dipstick Test is a lateral flow immunoassay for the rapid detection of propoxyphene in human urine at or above $3 0 0 ~ \mathrm { { n g / m L } }$ .

The Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipstick and QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard are lateral flow immunoassay for the rapid detection of multiple drugs and drug metabolites in human urine at or above the following cutoff concentration:

THC 11-nor- $\cdot \Delta 9$ -Tetrahydrocannabinol-9-carboxylic acid 50 ng/ml COC Benzoylecgonine 300 ng/ml OPI Morphine 300 ng/ml MET Methamphetamine 500 ng/ml AMP Amphetamine 1000 ng/ml PCP Phencyclidine 25 ng/ml BZO Oxazepam 300 ng/ml BAR Secobarbital 300 ng/ml MTD Methadone 300 ng/ml TCA Nortriptyline 1000 ng/ml MDMA 3,4-methylenedioxymethamphetamine 500 ng/ml OXY Oxycodone 100 ng/ml BUP Buprenorphine 10 ng/ml PPX Propoxyphene 300 ng/ml

These tests provide visual qualitative results and are intended for in vitro diagnostic use only. It is for prescription point-of-care use only and not intended for over-thecounter sale to non-professionals.

These tests provide only a preliminary test result. For a quantitative result or to confirm preliminary positive results obtained by the QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard, Fastect $^ \mathrm { { \textregistered } }$ II Drug Screen Dipstick or Fastect $^ \mathrm { \textregistered }$ II PPX Drug Screen Dipstick tests, a more specific alternative method such as Gas Chromatography/Mass Spectrometry (GC/MS) must be used. Clinical Consideration and professional judgment should be applied to any drug of abuse test results, particularly when a preliminary positive result is indicated.

3. Special conditions for use statement(s):

These tests are for prescription point-of-care use only and not intended for overthe-counter use.

4. Special instrument requirements:

Not applicable

# I. Device Description:

The Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipstick with Propoxyphene and QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard with Propoxyphene contain multiple drugs and drug metabolites in addition to Propoxyphene. Propoxyphene is added as a new analyte. The Fastect $^ \mathrm { \textregistered }$ II PPX Drug Screen Dipstick only contains the propoxyphene analyte. All dipstick and dipcard devices are based on the principle of highly specific immunochemical reactions between antigens and antibodies and all devices utilize a competitive immunoassay procedure in which an immobilized drug conjugate competes with the drug present in urine for limited antibody binding sites.

The Fastect $^ \mathrm { \textregistered }$ II PPX Drug Screen Dipstick, Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipstick and QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard devices are standardized to detect Propoxyphene in human urine at a cutoff concentration of $3 0 0 ~ \mathrm { { n g / m l } }$ . These tests can be performed without the use of any additional instruments.

A control band with a different antigen/antibody reaction is added to the immunochromatographic membrane strip and should always appear regardless of the presence of drug or metabolite. The appearance of the control band during testing indicates that the test has completed and the test is valid.

# J. Substantial Equivalence Information:

1. Predicate device name(s): ACON MULTI-CLIN Drug Screen Test Device

2. Predicate K number(s): k041685

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">Candidate Devices(QuickTox® Drug ScreenDipcard, Fastect® II PPX DrugScreen Dipstick and Fastect® IIDrug Screen Dipstick)</td><td colspan="1" rowspan="1">Predicate Device(ACON® multi-CLINTMDrug Screen Test Devicek041685)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Screening Device</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">HumanUrine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Competitive immunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Propoxyphene</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut-Off</td><td colspan="1" rowspan="1">300 ng/ml</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">10 ml</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Target User Population</td><td colspan="1" rowspan="1">For professional point of care</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Shelf Life</td><td colspan="1" rowspan="1">24 Months</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Testing Method</td><td colspan="1" rowspan="1">Lateral Flow Immunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antibody/Antigen</td><td colspan="1" rowspan="1">Mouse monoclonal antibodyPPX antigen</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">Candidate Devices(QuickTox® Drug ScreenDipcard and Fastect® IIDrug Screen Dipstick)</td><td colspan="1" rowspan="1">Predicate Device(ACON® multi-CLINTMDrug Screen Test Devicek041685)</td></tr><tr><td colspan="1" rowspan="1">Test Strip</td><td colspan="1" rowspan="1">Single Drug/Multi-Drug</td><td colspan="1" rowspan="1">Multi-Drug</td></tr><tr><td colspan="1" rowspan="1">Product Design</td><td colspan="1" rowspan="1">Dip method</td><td colspan="1" rowspan="1">Dip method and dropmethod</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Sealed pouch at 15-30°C</td><td colspan="1" rowspan="1">Sealed pouch at 2-30°C</td></tr><tr><td colspan="1" rowspan="1">Reading Time</td><td colspan="1" rowspan="1">5-30 minutes</td><td colspan="1" rowspan="1">5-8 hours</td></tr><tr><td colspan="1" rowspan="1">Internal ProceduralControls</td><td colspan="1" rowspan="1">Negative control line</td><td colspan="1" rowspan="1">Positive and negativecontrol lines</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None were referenced

# L. Test Principle:

The Fastect $^ \mathrm { \textregistered }$ II PPX Drug Screen Dipstick, Fastect $^ \mathrm { { \textregistered } }$ II Drug Screen Dipstick with Propoxyphene and QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard with Propoxyphene are based on the principle of highly specific immunochemical reactions between antigens and antibodies. All dipstick and dipcard devices utilize a competitive immunoassay procedure in which an immobilized drug conjugate competes with the drug present in urine for limited antibody binding sites.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were performed over ten days at three point-of-care sites using drug-free normal urine spiked with drug standards to the following concentrations: cutoff, $\pm 2 5 \%$ , $\pm 5 0 \%$ , $\pm 7 5 \%$ and $\pm 1 0 0 \%$ of the cutoff. A total of 30 samples were tested at cutoff, $\pm 2 5 \% , \pm 5 0 \% , \pm 7 5 \%$ and $+ 1 0 0 \%$ cutoff levels, respectively. A total of 60 samples were tested at negative (zero) level. Sample concentrations were confirmed by GC/MS. The intended users performed the testing by following the instructions for use.

PPX measured by QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard   

<table><tr><td rowspan=1 colspan=1>Conc.</td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Combined</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr></table>

PPX measured by Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipsticks   

<table><tr><td rowspan=1 colspan=1>Conc.</td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Combined</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr></table>

b. Linearity/assay reportable range:

Not applicable, the devices are intended for qualitative use.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

A control band with a different antigen/antibody reaction is added to the immunochromatographic membrane strip and should always appear regardless of the presence of the drug or its metabolites. The appearance of the control band during testing indicates that the test has completed and the test is valid.

Device Stability:

Accelerated studies have been conducted for one lot of Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipsticks and two lots of QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard kits. The manufacturer claims that when stored at room temperature $( 1 5 - 3 0 ^ { \circ } \mathrm { C } )$ , the product is stable for 24 months. Real time studies have been conducted to support a shelf life of 24 months at room temperature. Stability protocols and acceptance criteria were reviewed and considered acceptable.

Sample Storage and Stability:

Urine specimens may be refrigerated at $2 { - } 8 \mathrm { { \% } }$ for up to two days.

d. Detection limit:

Not applicable, this is a qualitative assay.

e. Analytical specificity:

Analytical specificity was established by spiking structurally related compounds into negative human urine. The lowest amount of compounds required to produce a positive response in Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipsticks and QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard and their corresponding $\%$ cross reactivity are displayed below.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>% cross reactivity</td></tr><tr><td rowspan=1 colspan=1>Propoxyphene</td><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Norpropoxyphene</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>60%</td></tr></table>

Potential interference from structurally unrelated and endogenous compounds was tested by spiking the potentially interfering compound into $\pm 5 0 \%$ of cutoff urine controls at a concentration of $1 0 0 , 0 0 0 ~ \mathrm { n g / m L }$ . No negative or positive interference was observed for the following compounds except furosemide in this study.

Acetaminophen (4-Acetamidophenol; APAP; N-Acetyl-p-aminophenol), Acetone, Acetylsalicylic acid (Aspirin), Albumin, Amoxapine, Amoxicillin, Ampicillin, l-Ascorbic Acid (Vitamin C), Aspartame, Atropine, Benzocaine (Ethyl p-Aminobenzoate), Bilirubin, d-Brompheniramine, Caffeine, Chloroquine, d,l-Chlorpheniramine, Chlorpromazine, l-Cotinine, Creatine, Creatinine, Cyclobenzaprine, Desipramine, Dextromethorphan, 4- Dimethylaminoantipyrine, Diphenhydramine, Dopamine (3- Hydroxytyramine), Doxylamine, l-Ephedrine, d,l-Ephedrine, l-Epinephrine, Erythromycin, Ethanol, 2-Ethylidene-1,5-Dimethyl-1-3,3-Diphenylpyrolidone, Furosemide\*, Gentisic acid, Glucose, Guaiacol, Glyceryl Ether, Hemoglobin, Hippuric acid, Hydrochlorothizide, Hydrocodone, Hydromorphone, Ibuprofen, Lidocaine, Methaqualone, Methoxyphenamine, Methylphenidate, Methadone, Nalidixic acid, Naloxone, d-Naproxen, Niacinamide, Norethindrone, Oxalic acid, Oxolinic acid, Papaverine, Penicillin-G (Benzylpenicillin), Pentazocine, Perphenazine, Pheniramine, Phenothiazine (Thiodiphenylamine), Phenylephrine, $\beta$ -Phenylethylamine, Procaine, Promethazine, Quinidine, Ranitidine, Riboflavin, Salicylic acid, Serotonin, Sodium Chloride, Sulfamethazine, Sulindac, Thiamine, Trimethobenzamide, Thioridazine, Trifluoperazine, Trimipramine Maleate, Tryptamine, d,l-Tryptophan, Tyramine, d,l-Tyrosine, Uric Acid, Verapamil, Zomepirac.

Possible false negative result for PPX may be observed for Furosemide at $\geq$ $6 0 { , } 0 0 0 \mathrm { n g / m L }$

The effects of $\mathrm { p H }$ and specific gravity of the specimen on the performance of QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard and Fastect $^ \mathrm { { \textregistered } }$ II Drug Screen Dipstick test kits at $\pm 5 0 \%$ of the cutoff levels were also tested. The results demonstrated no interference to results with pH range of 4.5-8.5 and specific gravity range of 1.005 to 1.030.

f. Assay cut-off:

Characterization of how the device performs analytically around the claimed cutoff concentration appears in the precision section, M.1.a, above.

2. Comparison studies:

a. Method comparison with predicate device:

A total of 84 urine specimens were evaluated with the QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard and Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipsticks devices. Of these 84 urine specimens, 42 were negative urine samples with 5 of them between cutoff and $- 5 0 \%$ cut-off levels. 42 were positive urine samples with 7 of them between cut-off and $+ 5 0 \%$ cut-off levels. Both the QuickTox $^ \mathrm { \textregistered }$ Drug Screen Dipcard and Fastect $^ \mathrm { \textregistered }$ II Drug Screen Dipstick devices were compared against the values obtained through GC/MS analysis. The results are presented in the table below:

<table><tr><td rowspan=2 colspan=1>CandidateDevice</td><td rowspan=2 colspan=1>CandidateDeviceResults</td><td rowspan=1 colspan=4>Clinical UrineCut-off (CO) Concentrations</td></tr><tr><td rowspan=1 colspan=1>-100% to&lt;-50%</td><td rowspan=1 colspan=1>≥ -50% to&lt; CO</td><td rowspan=1 colspan=1>≥CO to&lt;+50%</td><td rowspan=1 colspan=1>≥ +50%</td></tr><tr><td rowspan=2 colspan=1>QuickTox®Drug ScreenDipcard</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Fastect® ⅡIDrug ScreenDipsticks</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies: a. Clinical Sensitivity: Not applicable.

b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): The sponsor performed an optimal read time evaluation by testing 5 levels of urine controls in 20 replicates per level using both dip stick and dip card devices. The test results supported a reading time of 5 to 60 minutes. The sponsor chose a more conservative reading time of 5 to 30 minutes in their product inserts.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and does satisfy the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and does support a substantial equivalence decision.